Brainomix has announced the recent presentation of a series of studies at the European Stroke Organisation Conference (ESOC; 21–23 May, Helsinki, Finland), providing new evidence that further validates the impact of Brainomix 360 Stroke—the company’s artificial intelligence (AI)-based imaging solution.
At ESOC 2025, Gary Ford (University of Oxford, Oxford, UK) presented new and expanded results from what Brainomix describes as the “largest” prospective evaluation of stroke AI imaging software, showing that Brainomix 360 Stroke usage was associated with an increase in mechanical thrombectomy rates across evaluation sites. The solution’s impact was particularly significant in primary stroke centres (104% increase), but was also observed in comprehensive stroke centres (73% increase), representing—according to Brainomix—a network-wide benefit of Brainomix 360 Stroke for expanding patient access to the procedure.
The conference also saw Albert Yoo (Texas Stroke Institute, Plano, USA) present results from a research collaboration between Brainomix and the TESLA trial team, whose randomised study was originally published in the Journal of the American Medical Association (JAMA) in September 2024. In this new analysis of the trial data, Brainomix 360 Stroke was used to estimate the ischaemic core volume and degree of hypoattenuation on non-contrast computed tomography (NCCT) scans taken upon admission for the 276 large vessel occlusion (LVO) stroke patients included in the original study.
The results showed that both ischaemic core volume and the degree of hypoattenuation—as measured by net water uptake—modified the effect of mechanical thrombectomy and should therefore be considered when assessing the suitability of endovascular treatment in patients with large-core ischaemic stroke.
Brainomix also presented a new study with leading academic clinicians from the USA, exploring brain frailty as an independent predictor of functional outcome in patients undergoing mechanical thrombectomy. This topic will be included alongside other breakthrough research projects in an upcoming webinar that the company has organised with Ansaar Rai (West Virginia University, Morgantown, USA) and Waleed Brinjikji (Mayo Clinic, Rochester, USA) on 12 June, according to a company press release.
“This is an exciting study, where our next-generation biomarkers were able to assess brain frailty, finding it to be a useful criterion when assessing a patient’s suitability for mechanical thrombectomy and the likelihood of them achieving a good clinical outcome,” said George Harston, chief medical and innovation officer at Brainomix.
Brainomix notes in its recent release that it supported a number of additional studies presented at ESOC last week—including one from Amelia Adcock (West Virginia University, Morgantown, USA) on the results of a comparative analysis of Brainomix 360 Stroke and Viz.ai’s AI imaging solution demonstrating that, while both technologies accurately identified intracranial LVOs, the former did exhibit a higher sensitivity for more distal occlusions. Brainomix 360 Stroke was also the “only” CT perfusion solution that showed a significant association between perfusion deficit and National Institutes of Health stroke scale (NIHSS) scores.
Additionally, Esra Zhubi (Semmelweis University, Budapest, Hungary) presented results from a study where Brainomix 360 Stroke was used to assess collateral status on CT angiography, with the research team concluding that changes in collateral status during transfer for thrombectomy were strong predictors of post-thrombectomy outcomes in LVO patients.
Another presentation pertained to a research collaboration between Brainomix and Boston Medical Center (Boston, USA) assessing the accuracy of Brainomix 360 Stroke’s automated haemorrhage detection tool to identify intracerebral haemorrhage (ICH). Brainomix claims that its software exhibited high overall sensitivity (93%) and specificity (94%) across a total of 351 successfully processed cases, demonstrating its efficiency and efficacy for all subtypes of ICH detection, and its ability to provide a reliable triage and notification service to aid clinicians in identifying these cases.
Finally, a study conducted alongside leading stroke researchers in Czechia examined the utility of CT perfusion—processed with Brainomix 360 Stroke—to more effectively differentiate strokes from ‘stroke mimics’ in order to optimise care and reduce the risk of inappropriate treatment in stroke mimic patients.
